STUDY DESIGN AND METHODS: Donor/donation data were sourced from the Recipient Epidemiology and Donor Evaluation Study-III, which contains information from four US blood centers during 2012 through 2016. Multivariable logistic regression was used to assess prevalence of positive antibody screen by donor demographics, blood type, parity, and transfusion history.
RESULTS:
More than 2 million units were collected from 632,378 donors, with 0.51% of donations antibody screen positive and 0.77% of donors having at least one positive antibody screen. The most common antibody specificities were D (26.4%), E (23.8%), and K (21.6%). Regression analysis indicated that increasing age, female sex, D-negative status, and history of transfusion and pregnancy were positively associated with a positive antibody screen. Prior transfusion history was most strongly associated with a positive antibody screen, with donors reporting a prior transfusion having a higher adjusted odds ratio (3.9) of having a positive antibody screen compared to donors reporting prior pregnancy (adjusted odds ratio, 2.0). Though transfusion was a more potent immune stimulus for RBC alloantibody formation than pregnancy, the sheer number of previously pregnant donors contributed to pregnancy being a risk factor for the majority of clinically significant RBC alloantibodies detected in females.
CONCLUSION: These findings on prevalence of and risk factors for RBC antibodies may have implications for future medical care of donors and for operations at blood centers.
antibody screening and crossmatch policies, due in part to previously formed RBC alloantibodies that fall below the level of detection by transfusion services. 3 Besides the transfusion setting, RBC alloantibodies are also appreciated to be clinically significant during pregnancy, 4 with algorithms defined for screening women throughout pregnancy and for intervening when certain antibody titers are reached or when certain antibody characteristics are observed. 5 Hemolytic disease of the fetus and newborn remains a clinical concern despite RhIg, with this therapy being targeted solely against anti-D alloimmunization and with access to RhIg being limited in some parts of the world. 6 Current US regulations from the AABB Standards require that serum or plasma from blood donors be tested for unexpected antibodies to RBC antigens. 7 If this is not completed, the Food and Drug Administration's Code of Federal Regulations require that a minor crossmatch, using donor plasma and recipient cells, be confirmed to be compatible prior to transfusion. 8 Because of these regulations, essentially all blood collected at US blood centers undergoes RBC antibody screening, though testing methodologies vary. Unlike human leukocyte antigen alloantibodies, which have been extensively studied in blood donors as part of transfusion-related acute lung injury mitigation efforts, 9,10 few large studies have investigated the prevalence of RBC alloantibodies in healthy blood donors.
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The Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) blood donor/blood donation database, established in 2012 and consisting of data from four geographically diverse blood centers across the United States, provides an opportunity to investigate RBC alloantibody prevalence and epidemiologic associations in healthy blood donors. In this manuscript, we describe the prevalence of positive RBC antibody screens in blood donations and donors in this database, investigate demographic and other associations with antibodies, and consider implications of antibodies for blood donors and blood centers alike.
MATERIALS AND METHODS

Database structure
The REDS-III blood donor/donation database involves four geographically diverse blood centers located in Connecticut, Pennsylvania, Wisconsin, and California (https://reds-iii.rti. org/REDSProgram.aspx).
Institutional Review Board approval for constructing this database was obtained by each participating site and the data coordinating center. Data collected in this database are subject to the National Heart, Lung, and Blood Institute (NHLBI) Policy for Data Sharing from Clinical Trials and Epidemiological Studies for eventual release as a public use data set.
Study variables
This analysis includes data collected over 4.5 years, from mid-2012 through the end of 2016. Data evaluated included donor age, sex, race, ethnicity, ABO type, D type, RBC antibody screen results, antibody screen test method, and if available, RBC antibody identification. Lifetime transfusion and pregnancy data were obtained from a supplemental donor questionnaire routinely obtained at the time of donation. If more than one donation existed from a donor, results from the most recent supplemental questionnaire were analyzed.
Each participating blood center used its own method for determining the presence of RBC antibodies and, in some instances, for identifying the antibody specificity. Antibody screening platforms included solid phase (two centers), gel card (one center), and enhanced tube (one center). The classification of RBC alloantibodies used in this study was recently published.
14 Clinically significant alloantibodies that were categorized included: D, C, c, E, e, Cw, G, V, f, Jsa, Kpa, K, k, Jka, Jkb, Fya, Fyb, M (IgG), S, s, U, and Lutheran. Donors with only warm autoantibodies, cold autoantibodies, or nonspecific antibodies were not counted as having clinically significant alloantibodies.
Statistical analysis
The primary outcome was the presence of a positive RBC antibody screen and its association with donor and/or blood center characteristics. 
Data by blood center
The four blood centers that contributed data to this project will be referred to as Centers 1 through 4. Centers 1 and 2 used a solid phase antibody detection platform, Center 3 used a gel card agglutination platform, and Center 4 used an enhanced tube testing platform for RBC antibody screening. Whereas all centers completed RBC antibody screens on essentially all donations, the extent of RBC antibody identification workups varied by center and by year. Center 3 had the most complete antibody identification data with antibody specificity results reported for more than 96% of positive antibody screens. Of 618 donors (0.4% of all donors) with a positive RBC alloantibody screen at this center, 417 (67.5%) had a clinically significant antibody identified. A minority of donors (116 of 618, 18.8%) with a positive RBC antibody screen had nonspecific or naturally occurring antibodies identified (Fig. S1C , available as supporting information in the online version of this paper). The remainder had a cold autoantibody, a non-clinically significant antibody, or no antibody ultimately identified.
Demographics of donors with a positive RBC antibody screen
Donor demographic data are shown in Table 1 , and results of the univariate analysis evaluating the association of donor demographics with antibody screen results are summarized in Table S1 (available as supporting information in the online version of this paper). Significant unadjusted predictors for having a positive antibody screen included sex, race, ethnicity, and D status (p < 0.0001 for all (Fig. 2) ). Blood group was less strongly associated with a positive antibody screen (p < 0.02), with blood group O (2,218/292,686 = 0.76%), blood group A (1,818/231,712 = 0.78%), blood group B (570/79,294 = 0.72%), and blood group AB (245/27,719 = 0.88%) donors having a positive antibody screen.
Blood donors ranged from 16 years of age to older than 80. An increase in the odds of having a positive RBC antibody screen was seen with increasing age (Table S1) , with donors older than 60 years being more likely to have a positive screen compared to donors 16 to 19 years of age (p < 0.0001). Similar trends were observed in males and in females, with females having a higher prevalence of positive RBC antibody screens than males at all ages (Fig. 3 ).
Transfusion and pregnancy history
The supplemental data form completed at the blood centers involved in this study asked donors if they had ever been transfused or pregnant (and, if so, the number of past pregnancies). Table 2 summarizes the data recorded from the most recent supplemental data form from each donor. A total of 2.9% of donors reported being previously transfused, and female donors (3.5%; 11,235 of 317,566) were more likely to have been previously transfused than male donors (2.4%; 7,420 of 314,829). Prior transfusion history was a very strong risk factor for having a positive antibody screen: 3.6% (670 of 18,654) of previously transfused donors had a positive screen, compared to 0.61% (3,303 of 540,088) of never transfused donors (p < 0.0001); donors with a history of RBC transfusion had a more than sixfold unadjusted odds of having a positive antibody screen compared to nevertransfused donors (Table S1) . Pregnancy history was a risk factor for having a positive antibody screen: 1.4% (2,058 of 145,197) of female donors with one or more pregnancies had a positive antibody screen, compared to 0.5% (652 of 139,468) of female donors without prior pregnancies (p < 0.0001); previously pregnant female donors had a greater than threefold unadjusted odds of having a positive screen compared to never-pregnant female donors (Table S1 ). The number of past pregnancies was associated with antibody screen positivity prevalence in females (Fig. 4B) , and increasing pregnancy number also remained a weak risk factor for having a positive antibody screen in never-transfused females (Fig. 4C ).
RBC alloantibody specificity
Most donors (86.2%) across the four blood centers with a clinically significant antibody identified had just one Figs. 5A and 5B. The distribution of antibody specificities varied by sex, with anti-D being more prevalent in females and anti-K being more prevalent in males (Fig. 5C) . A total of 840 clinically significant antibodies were identified and reported in females. Of these, 394 of 840 (46.9%) were present in donors who reported that they had previously been pregnant but never transfused, 259 of 840 (30.8%) were present in donors who reported being previously transfused and previously pregnant, 37 of 840 (4.4%) were present in donors who were neither previously transfused nor pregnant, and 29 of 840 (3.4%) were present in previously transfused but never-pregnant donors. These data, when viewed with the total percentage of females in each of these categories (Table 2) in mind, highlight the immunogenicity of RBC transfusion: for example, 0.75% of females were previously transfused but never pregnant, yet this group contributed to 3.4% of the clinically significant antibodies identified. The distribution of specificities of RBC alloantibodies in females presumably induced solely through reported pregnancy were different than those presumably induced solely through reported transfusion (Fig. 5D ).
Multivariate analysis of antibody screen positivity
After adjusting for the other covariates, patient age (p < 0.0001), sex (including pregnancy history) (p < 0.0001), D status (p < 0.0001), transfusion history (p < 0.0001), and blood center (p < 0.0001) were all independently associated with the odds of having a positive antibody screen ( Fig. 6A and Table S2 , available as supporting information in the online version of this paper). Missing data were specifically omitted when modeling the data; 0.12% were missing antibody screen results, 0.15% were missing blood group (ABO/D), 12% were missing transfusion history, and 11% of females were missing pregnancy history. Donors with a reported transfusion history had nearly a fourfold adjusted odds of having a positive antibody screen (OR, 3.9; 95% CI, 3.6-4.3; p < 0.0001). Previously pregnant females had double the adjusted odds of having a positive antibody screen in comparison to males (OR, 2.0; 95% confidence interval [CI], 1.8-2.1; p < 0.0001), and donors who were D negative also had a nearly two-fold increased odds of having a positive screen in comparison to D-positive individuals (OR, 1.7; 95% CI, 1.6-1.8; p < 0.0001). Finally, increasing age was associated with higher odds for a positive antibody screen with a sixfold difference across age groups.
Blood center emerged as one of the most highly significant variables to impact antibody screen positive prevalence. Using Center 2 as a referent, the adjusted odds of having a positive antibody screen at Center 1 was 5.6 (95% CI, 5.0-6.3), at Center 3 was 1.8 (95% CI, 1.5-2.0), and at Center 4 was 2.5 (95% CI, 2.2-2.8). We repeated the multivariate analysis separately for each center and found similar patterns of demographic, transfusion, and pregnancy associations with having positive antibody screen (Fig. S2 , available as supporting information in the online version of this paper). Multivariate analysis of factors associated with clinically significant alloantibodies The primary outcome of this study was antibody screen positivity, as these data were available from all blood centers. Because Center 3 had the most complete antibody identification data, the multivariate analysis was repeated after confining it to donors at this center, not just with a positive antibody screen but also with at least one clinically significant RBC alloantibody identified. After adjusting for the other covariates, patient age, pregnancy history, D status, and transfusion history (p < 0.0001 for each) independently affected the adjusted odds of having a clinically significant RBC alloantibody present (Fig. S3 , available as supporting information in the online version of this paper). Donors with a reported transfusion history had a more than 11-fold adjusted odds of having a clinically significant RBC alloantibody, previously pregnant females had a nearly fourfold adjusted odds compared to males (OR, 3.9; 95% CI, 3.1-5.0; p < 0.0001), and donors who were D negative had a more than threefold increased odds in comparison to D-positive individuals (OR, 3.3; 95% CI, 2.7-4.0; p < 0.0001). Increasing age was associated with a higher adjusted OR.
DISCUSSION
The NHLBI REDS-III donor/donation database, containing data from more than 600,000 donors and 2 million blood donations, allowed this study to be completed. This is the largest such study ever completed, consisting of blood donors from geographically diverse areas in the United States. The juxtaposition of donor demographic information, donor questionnaire information containing lifelong transfusion and pregnancy histories, and longitudinal RBC antibody screen data allowed a unique vantage point for data analysis.
In this study, a positive antibody screen was noted overall in 0.5% of donations and 0.77% of blood donors at the four centers over the 4.5-year study period, utilizing methodologies ranging from solid phase to gel card to tube testing. A clinically significant RBC alloantibody was identified in the majority (65%) of donors with positive antibody screens at the center with the most extensive antibody identification data reported. These numbers are generally consistent with previously published smaller blood donor studies, 11, 12, 15, 16 and are lower than those described in patients. [17] [18] [19] The actual prevalence of RBC alloimmunization is potentially underestimated in this and other donor studies, as donor centers may not desire the same level of antibody detection sensitivity as hospitals do in pretransfusion testing. Although attention has recently been paid to risk factors for human leukocyte antigen alloimmunization in blood donors as part of transfusion-related acute lung injury risk mitigation planning, 9 few studies to date have evaluated demographic or exposure risk factors that may predispose blood donors to having positive RBC antibody screens. By univariate and multivariable analysis, our study found many of the same demographic associations with RBC alloimmunization as a recent REDS-III recipient database study 14 and other studies, including being older, 20 female, 21 and D negative. 22 Our multivariate analysis showed an increase in positive antibody screens with age in both males and females. We also report a small percentage of never-transfused, never-pregnant donors with a positive antibody screen. These data may be due in part to nonspecific reactivity, to donors having been unknowingly transfused during past surgeries, or to transfusion histories answered incorrectly on the donor questionnaire. They may suggest that RBC alloantibodies are formed after environmental exposures or are "naturally occurring" to a greater extent than previously appreciated. 23 RBC alloimmunization prevalence has been shown to be higher in females than in males in multiple studies, 14, 21, 24 including those in blood donors. 11, 25, 26 Pregnancy-associated RBC alloimmunization has not previously been extensively studied, due in part to difficulties in uniformly obtaining and documenting lifetime pregnancy histories and in comparing these to lifetime transfusion histories. The blood donor questionnaires provided us with a unique opportunity to investigate the presumed cause of alloimmunization in females and to look at the specificity of pregnancy-induced antibodies. Past transfusion was more common in females than in males, and was the single strongest adjusted risk factor for having a positive antibody screen or for having a clinically significant RBC alloantibody in males and in females. As further described in the recently published Blood Group Antigen Matching on Gestational Outcomes (AMIGO) study, 27 pregnancy was also an important risk factor for having a positive antibody screen, likely due to the sheer number of previously pregnant compared to previously transfused females. Anti-D was surprisingly overrepresented among previously pregnant but never-transfused females, raising the question of access to RhIg or to RhIg failures. A high prevalence of D alloimmunization was also described in females by Giblett 26 in a 1977
blood donor study, but that was in a pre-RhIg era. Among donors with a single type of exposure (transfusion or pregnancy), anti-K was more commonly observed in previously transfused than in previously pregnant donors, raising the question of whether the immunogenicity of blood group antigens may vary based on exposure type. These data further raise the question of whether prophylactically matching RBC transfusions for the K antigen in females of childbearing age may be beneficial. One consideration in evaluating pregnancy-versus transfusion-induced antibodies is that pregnancy-associated antibodies may have lower rates of evanescence than transfusion-associated antibodies. 28 Further, unrecognized or unreported pregnancies must also be considered. Collectively, these data emphasize the importance of taking past pregnancies into consideration in RBC alloimmunization studies, while simultaneously emphasizing the potency of transfused RBCs in stimulating RBC alloantibody formation. The implications of a blood donor having a positive antibody screen are quite different for the blood center than those of a potential transfusion recipient having a positive antibody screen are for a transfusion service/hospital. Blood centers strive to produce transfusable products from all donations, and the presence of a positive antibody screen prevents some blood components from being transfusable. For example, no plasma, platelets, or cryoprecipitate were produced for transfusion from any antibody-positive donor at any of the four centers in this study. RBC units from antibody screen-positive donations were produced for transfusion at two of the blood centers, as these centers had customers willing to accept products labeled with a tag describing the detected antibody. The two other blood centers, however, did not produce transfusable RBCs from antibody screenpositive donors. Donor RBC antibodies in RBC units rarely impact transfusion outcomes 29 but may interfere with future antibody screen results in the transfusion recipients due to passively transferred antibody. This passively transferred antibody may, in turn, impact future transfusions for such recipients. As such, some but not all hospitals are willing to accept RBCs from antibody-positive donors. A better understanding of risk factors associated with a positive RBC antibody screen, or with a persistently positive antibody screen over time, may allow blood centers to make decisions that impact the number of discarded donations. Implications of a positive antibody screen for the donors themselves must also be considered. There are no mandates in the United States to inform the donors of their antibody screen results or to identify the antibody specificity, though communicating this information to donors may be useful for future transfusions or pregnancies. A consistent approach to donor notification as well as to deferral practices after one or more positive RBC antibody screens may be beneficial. Such approaches and practices varied among centers in this study, with some centers having written policies to notify blood donors of a positive antibody screen and to initiate a 1-year RBC donation deferral after a positive screen and a permanent deferral after a second positive antibody screen, and with others leaving these decisions to the discretion of the blood center medical director.
Limitations of a large retrospective epidemiologic study such as this deserve consideration. First, each blood center used different techniques for antibody screening, with different levels of sensitivity. Blood center alone emerged in the multivariate analysis as the strongest independent risk factor for having a positive antibody screen, with two blood centers that used similar antibody screening methodologies having the largest difference in reported antibody screen-positive prevalence. Other than technical differences, other possible explanations include differences in donor demographics, donor recruitment, environmental exposures, and donor deferral practices. Despite differences in the sensitivity of different antibody screening techniques, however, similar trends in ORs were observed by center for the impact of demographic, transfusion, and pregnancy history data on antibody screen results. Second, some but not all centers routinely completed an antibody identification after a positive screen. Thus, donors from all centers are not equally represented in the antibody specificity data. Third, as with all retrospective RBC alloantibody studies, the described prevalence likely underestimates the true antibody prevalence, given transfusion associated antibody evanescence patterns. 30 Finally, the data on transfusion and pregnancy history may not be fully accurate, given the potential for misreporting and lack of validation with medical or other records. In summary, this is the largest study of RBC alloimmunization in blood donors, including data from more than 600,000 blood donors in the United States donating more than 2 million units over a 4.5-year period. Whereas the prevalence of positive RBC antibody screens in blood donors was relatively low, the absolute number of donations impacted by positive screens was not trivial. Our findings may have implications for the donors themselves, for future medical/surgical care, and pregnancies. These findings also have operational implications for blood centers, as they strive to use each donation to the greatest extent possible.
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